Aequus Pharmaceuticals Inc. (AQSZF)
OTCMKTS
· Delayed Price · Currency is USD
0.0035
0.00 (0.00%)
At close: Jun 24, 2025
Aequus Pharmaceuticals Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 0.76 | 0.58 | 0.25 | 1.38 | 2.71 | 2.59 | Upgrade
| |
Revenue Growth (YoY) | 252.34% | 129.21% | -81.53% | -49.17% | 4.71% | 58.81% | Upgrade
|
Cost of Revenue | 0.32 | 0.25 | 0.11 | 0.1 | 0.04 | - | Upgrade
|
Gross Profit | 0.43 | 0.33 | 0.14 | 1.28 | 2.67 | 2.59 | Upgrade
|
Selling, General & Admin | 2.04 | 2.46 | 2.66 | 3.69 | 3.98 | 3.32 | Upgrade
|
Research & Development | - | - | 0.3 | 0.17 | 0.3 | 0.05 | Upgrade
|
Operating Expenses | 2.04 | 2.46 | 2.96 | 3.86 | 4.28 | 3.37 | Upgrade
|
Operating Income | -1.6 | -2.13 | -2.82 | -2.58 | -1.61 | -0.78 | Upgrade
|
Interest Expense | -0.27 | -0.25 | -0.15 | -0.13 | -0.21 | -0.29 | Upgrade
|
Interest & Investment Income | 0 | 0 | 0 | 0.02 | 0.01 | 0 | Upgrade
|
Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0 | 0.04 | -0 | -0 | Upgrade
|
Other Non Operating Income (Expenses) | - | - | - | -0.57 | - | - | Upgrade
|
EBT Excluding Unusual Items | -1.88 | -2.38 | -2.96 | -3.21 | -1.81 | -1.06 | Upgrade
|
Asset Writedown | -0.49 | - | - | - | - | - | Upgrade
|
Other Unusual Items | 0.2 | 0.2 | - | - | - | 0.02 | Upgrade
|
Pretax Income | -2.16 | -2.18 | -2.96 | -3.21 | -1.81 | -1.05 | Upgrade
|
Net Income | -2.16 | -2.18 | -2.96 | -3.21 | -1.81 | -1.05 | Upgrade
|
Net Income to Common | -2.16 | -2.18 | -2.96 | -3.21 | -1.81 | -1.05 | Upgrade
|
Shares Outstanding (Basic) | 133 | 133 | 133 | 133 | 129 | 93 | Upgrade
|
Shares Outstanding (Diluted) | 133 | 133 | 133 | 133 | 129 | 93 | Upgrade
|
Shares Change (YoY) | - | - | - | 2.94% | 38.28% | 15.86% | Upgrade
|
EPS (Basic) | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | Upgrade
|
EPS (Diluted) | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | Upgrade
|
Free Cash Flow | -1.1 | -1.66 | -2.29 | -1.95 | -1.18 | -0.82 | Upgrade
|
Free Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | Upgrade
|
Gross Margin | 57.21% | 56.88% | 56.36% | 92.49% | 98.42% | 100.00% | Upgrade
|
Operating Margin | -211.57% | -364.10% | -1106.45% | -187.17% | -59.22% | -30.08% | Upgrade
|
Profit Margin | -284.96% | -372.74% | -1163.11% | -232.65% | -66.66% | -40.32% | Upgrade
|
Free Cash Flow Margin | -145.41% | -283.44% | -899.97% | -141.51% | -43.33% | -31.52% | Upgrade
|
EBITDA | - | -2.12 | -2.81 | -2.58 | -1.6 | -0.69 | Upgrade
|
EBITDA Margin | - | - | - | -186.67% | -58.91% | -26.56% | Upgrade
|
D&A For EBITDA | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.09 | Upgrade
|
EBIT | -1.6 | -2.13 | -2.82 | -2.58 | -1.61 | -0.78 | Upgrade
|
EBIT Margin | -211.57% | - | - | -187.17% | -59.22% | -30.08% | Upgrade
|
Revenue as Reported | - | - | - | 1.38 | 2.71 | 2.59 | Upgrade
|
Advertising Expenses | - | 0.28 | 0.23 | 0.24 | 0.22 | 0.1 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.